Sepsis clinical trials at UCSF

6 in progress, 4 open to eligible people

Showing trials for

  • TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

    open to eligible people ages 18-85

    The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).

    San Francisco 5391959, California 5332921 and other locations

  • Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

    open to eligible people ages 2 months to 17 years

    The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.

    San Francisco 5391959, California 5332921 and other locations

  • Stress Hydrocortisone In Pediatric Septic Shock

    open to eligible people ages 1 month to 17 years

    SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL) (secondary outcome), as assessed at 28 days following study enrollment (randomization).

    Oakland 5378538, California 5332921 and other locations

  • Role of Transposable Elements in Septic Immune Aging

    open to eligible people ages 18 years and up

    The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is: 1. Do transposable elements prematurely age the immune systems of patients with sepsis? 2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU? 3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU? Participants will have blood drawn from them but will not be subjected to additional interventions.

    San Francisco 5391959, California 5332921

  • Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

    Sorry, in progress, not accepting new patients

    Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock

    San Francisco 5391959, California 5332921 and other locations

  • APS Phenotyping Study

    Sorry, not currently recruiting here

    The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and/or pneumonia.

    San Francisco 5391959, California 5332921 and other locations

Our lead scientists for Sepsis research studies include .

Last updated: